Data/hora: 19/05/2024 01:26:01

Provedor de dados: 	Brazilian Journal of Pharmaceutical Sciences	
País: 	Brazil	
Título: 	Synergistic effect of microRNA and albumin-bound nanoparticles for inhibition of glioblastoma cancer cell proliferation	
Autores: 	Shariatnasery,Maria; Irani,Shiva; Soleimani,Masoud; Goodarzi,Navid; Dinarvand,Rassoul.	
Data: 	2020-01-01	
Ano: 	2020	
Palavras-chave: 	MiR-34a; Glioblastoma; Albumin; Paclitaxel; Nanoparticles; Combination therapy.	
Resumo: 	The functional significance of upregulation miR-34a in combination with albumin-bound paclitaxel nanoparticles in U251 glioblastoma cell line has been evaluated. The MTT assay determined that miR-34a and albumin-bound paclitaxel nanoparticles can reduce cell viability, but the combination of both factors has a stronger effect on cell viability. The application of qRT-PCR has demonstrated that the transduction of miR-34a could lead to exogenous upregulation of miR-34a level and downregulation of SURVIVIN. Moreover, treatment of U251 cells with miR-34a and nanoparticles together considerably inhibit SURVIVIN expression compared to miR-34a and nanoparticles alone. Flow cytometry showed that upon miR-34a overexpression cell cycle arrested in G1 phase, while treatment with nanoparticles increased the cell population in G2 phase. Upregulation of miR-34a along with treatment with nanoparticles elevated the number of cells arrested in G1/ G2 phases of the cell cycle. Expression of miR-34a with albumin-bound paclitaxel nanoparticles reduced cell viability, downregulated SURVIVIN and enhanced cell cycle arrest in G1/G2 phases. Thus, the upregulation of miR-34a with these nanoparticles are potential candidates therapeutic for glioblastoma cancer.	
Tipo: 	Info:eu-repo/semantics/article	
Idioma: 	Inglês	
Identificador: 	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502020000100535	
Editor: 	Universidade de São Paulo, Faculdade de Ciências Farmacêuticas	
Relação: 	10.1590/s2175-97902019000318306	
Formato: 	text/html	
Fonte: 	Brazilian Journal of Pharmaceutical Sciences  v.56 2020	
Fonte: 	info:eu-repo/semantics/openAccess